Skip to Content

'
Vashisht G. Yennu-Nanda, Ph.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
7435 Fannin
Unit Number: Unit 904
Houston, TX 77054
Room Number: 2SCR4.1030
Phone: (713) 792-7731
Fax: (713) 563-3424

Education & Training

Degree-Granting Education

2000 The University of Hyderabad, Hyderabad, India, PHD, Biochemistry

Postgraduate Training

3/2000-4/2005 Postdoctoral, Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Michael W. Van Dyke, Ph.D.

Selected Publications

Peer-Reviewed Original Research Articles
1. Vashisht Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70(21):8736-47, 11/2010. e-Pub 10/2010. PMID: 20959481.
2. Altman MK, Vashisht Gopal YN(Co-First author), Jia W, Yu S, Hall H, Mills GB, McGinnis AC, Bartlett MG, Jiang G, Madan D, Prestwich GD, Xu Y, Davies MA, Murph MM. Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Mol Cancer 9:140, 2010. e-Pub 6/2010. PMCID: PMC2895597.
3. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Vashisht Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res 15(24). e-Pub 12/2009. PMCID: PMC2805170.
4. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Vashisht Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MA. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 8(8):2079-85, 8/2009. e-Pub 8/2009. PMID: 19671763.
5. Baby J, Pickering BF, Vashisht Gopal YN, Van Dyke MW. Constitutive and inducible nuclear factor-kappaB in immortalized normal human bronchial epithelial and non-small cell lung cancer cell lines. Cancer Lett 255(1):85-94, 9/2007. e-Pub 5/2007. PMID: 17493745.
6. Vashisht Gopal YN, Arora TS, Van Dyke MW. Parthenolide Specifically Depletes Histone Deacetylase 1 Protein and Induces Cell Death through Ataxia Telangiectasia Mutated. Chem Biol 14(7):813-23, 7/2007.
7. Vashisht Gopal YN, Van Dyke MW. Depletion of histone deacetylase protein: a common consequence of inflammatory cytokine signaling? Cell Cycle 5(23):2738-43, 12/2006. e-Pub 12/2006. PMID: 17172847.
8. Vashisht Gopal YN, Konuru N, Kondapi AK. Topoisomerase II antagonism and anticancer activity of coordinated derivatives of [RuCl(2)(C(6)H(6))(dmso)]. Arch Biochem Biophys 401(1):53-62, 5/2002. PMID: 12054487.
9. Vashisht Gopal YN, Jayaraju D, Kondapi AK. Topoisomerase II poisoning and antineoplastic action by DNA-nonbinding diacetyl and dicarboxaldoxime derivatives of ferrocene. Arch Biochem Biophys 376(1):229-35, 4/2000. PMID: 10729210.
10. Jayaraju D, Vashisht Gopal YN, Kondapi AK. Topoisomerase II is a cellular target for antiproliferative cobalt salicylaldoxime complex. Arch Biochem Biophys 369(1):68-77, 9/1999. PMID: 10462441.
11. Vashisht Gopal YN, Jayaraju D, Kondapi AK. Inhibition of topoisomerase II catalytic activity by two ruthenium compounds: a ligand-dependent mode of action. Biochemistry 38(14):4382-8, 4/1999. PMID: 10194357.

Last updated: 3/11/2013